These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
452 related articles for article (PubMed ID: 18362070)
1. Scaffold oriented synthesis. Part 2: Design, synthesis and biological evaluation of pyrimido-diazepines as receptor tyrosine kinase inhibitors. Gracias V; Ji Z; Akritopoulou-Zanze I; Abad-Zapatero C; Huth JR; Song D; Hajduk PJ; Johnson EF; Glaser KB; Marcotte PA; Pease L; Soni NB; Stewart KD; Davidsen SK; Michaelides MR; Djuric SW Bioorg Med Chem Lett; 2008 Apr; 18(8):2691-5. PubMed ID: 18362070 [TBL] [Abstract][Full Text] [Related]
2. 7-Aminopyrazolo[1,5-a]pyrimidines as potent multitargeted receptor tyrosine kinase inhibitors. Frey RR; Curtin ML; Albert DH; Glaser KB; Pease LJ; Soni NB; Bouska JJ; Reuter D; Stewart KD; Marcotte P; Bukofzer G; Li J; Davidsen SK; Michaelides MR J Med Chem; 2008 Jul; 51(13):3777-87. PubMed ID: 18557606 [TBL] [Abstract][Full Text] [Related]
3. Tricyclic azepine derivatives: pyrimido[4,5-b]-1,4-benzoxazepines as a novel class of epidermal growth factor receptor kinase inhibitors. Smith L; Piatnitski EL; Kiselyov AS; Ouyang X; Chen X; Burdzovic-Wizemann S; Xu Y; Pan W; Chen X; Wang Y; Rosler RL; Patel SN; Chiang HH; Milligan DL; Columbus J; Wong WC; Doody JF; Hadari YR Bioorg Med Chem Lett; 2006 Mar; 16(6):1643-6. PubMed ID: 16412636 [TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of 5-substituted 1,4-dihydroindeno[1,2-c]pyrazoles as multitargeted receptor tyrosine kinase inhibitors. Akritopoulou-Zanze I; Albert DH; Bousquet PF; Cunha GA; Harris CM; Moskey M; Dinges J; Stewart KD; Sowin TJ Bioorg Med Chem Lett; 2007 Jun; 17(11):3136-40. PubMed ID: 17391959 [TBL] [Abstract][Full Text] [Related]
5. Isothiazolopyrimidines and isoxazolopyrimidines as novel multi-targeted inhibitors of receptor tyrosine kinases. Ji Z; Ahmed AA; Albert DH; Bouska JJ; Bousquet PF; Cunha GA; Glaser KB; Guo J; Li J; Marcotte PA; Moskey MD; Pease LJ; Stewart KD; Yates M; Davidsen SK; Michaelides MR Bioorg Med Chem Lett; 2006 Aug; 16(16):4326-30. PubMed ID: 16735117 [TBL] [Abstract][Full Text] [Related]
6. The development of 2-benzimidazole substituted pyrimidine based inhibitors of lymphocyte specific kinase (Lck). Sabat M; VanRens JC; Laufersweiler MJ; Brugel TA; Maier J; Golebiowski A; De B; Easwaran V; Hsieh LC; Walter RL; Mekel MJ; Evdokimov A; Janusz MJ Bioorg Med Chem Lett; 2006 Dec; 16(23):5973-7. PubMed ID: 16997556 [TBL] [Abstract][Full Text] [Related]
7. N-(4-(6,7-Disubstituted-quinolin-4-yloxy)-3-fluorophenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors. Mannion M; Raeppel S; Claridge S; Zhou N; Saavedra O; Isakovic L; Zhan L; Gaudette F; Raeppel F; Déziel R; Beaulieu N; Nguyen H; Chute I; Beaulieu C; Dupont I; Robert MF; Lefebvre S; Dubay M; Rahil J; Wang J; Ste-Croix H; Robert Macleod A; Besterman JM; Vaisburg A Bioorg Med Chem Lett; 2009 Dec; 19(23):6552-6. PubMed ID: 19854051 [TBL] [Abstract][Full Text] [Related]
8. Discovery of pyrimidine benzimidazoles as Src-family selective Lck inhibitors. Part II. Zhang G; Ren P; Gray NS; Sim T; Wang X; Liu Y; Che J; Dong W; Tian SS; Sandberg ML; Spalding TA; Romeo R; Iskandar M; Wang Z; Seidel HM; Karanewsky DS; He Y Bioorg Med Chem Lett; 2009 Dec; 19(23):6691-5. PubMed ID: 19854052 [TBL] [Abstract][Full Text] [Related]
9. Novel tricyclic azepine derivatives: Biological evaluation of pyrimido[4,5-b]-1,4-benzoxazepines, thiazepines, and diazepines as inhibitors of the epidermal growth factor receptor tyrosine kinase. Smith L; Wong WC; Kiselyov AS; Burdzovic-Wizemann S; Mao Y; Xu Y; Duncton MA; Kim K; Piatnitski EL; Doody JF; Wang Y; Rosler RL; Milligan D; Columbus J; Balagtas C; Lee SP; Konovalov A; Hadari YR Bioorg Med Chem Lett; 2006 Oct; 16(19):5102-6. PubMed ID: 16887347 [TBL] [Abstract][Full Text] [Related]
10. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity. Martin MW; Newcomb J; Nunes JJ; Boucher C; Chai L; Epstein LF; Faust T; Flores S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Kim JL; Middleton S; Morgenstern K; Oliveira-dos-Santos A; Patel VF; Powers D; Rose P; Tudor Y; Turci SM; Welcher AA; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Ermann M; Johnston D; Saluste CG J Med Chem; 2008 Mar; 51(6):1637-48. PubMed ID: 18278858 [TBL] [Abstract][Full Text] [Related]
11. Discovery and in vitro evaluation of potent kinase inhibitors: Pyrido[1',2':1,5]pyrazolo[3,4-d]pyrimidines. Alberti MJ; Auten EP; Lackey KE; McDonald OB; Wood ER; Preugschat F; Cutler GJ; Kane-Carson L; Liu W; Jung DK Bioorg Med Chem Lett; 2005 Aug; 15(16):3778-81. PubMed ID: 15993060 [TBL] [Abstract][Full Text] [Related]
12. Novel 5-substituted, 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors with antiangiogenic and antitumor activity. Gangjee A; Zeng Y; Ihnat M; Warnke LA; Green DW; Kisliuk RL; Lin FT Bioorg Med Chem; 2005 Sep; 13(18):5475-91. PubMed ID: 16039863 [TBL] [Abstract][Full Text] [Related]
13. Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation. Harmange JC; Weiss MM; Germain J; Polverino AJ; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; DiPietro L; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Martin MW; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Wang L; White RD; Whittington DA; Zanon R J Med Chem; 2008 Mar; 51(6):1649-67. PubMed ID: 18324761 [TBL] [Abstract][Full Text] [Related]
14. Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation. DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Chai L; Chaffee SC; Deak HL; Epstein LF; Faust T; Gallant P; Gore A; Gu Y; Henkle B; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; Zhao H; Zhu L; Zhu X J Med Chem; 2008 Mar; 51(6):1681-94. PubMed ID: 18321037 [TBL] [Abstract][Full Text] [Related]
15. Triazolo[1,5-a]pyrimidines as novel CDK2 inhibitors: protein structure-guided design and SAR. Richardson CM; Williamson DS; Parratt MJ; Borgognoni J; Cansfield AD; Dokurno P; Francis GL; Howes R; Moore JD; Murray JB; Robertson A; Surgenor AE; Torrance CJ Bioorg Med Chem Lett; 2006 Mar; 16(5):1353-7. PubMed ID: 16325401 [TBL] [Abstract][Full Text] [Related]
16. Entry into a new class of protein kinase inhibitors by pseudo ring design. Furet P; Caravatti G; Guagnano V; Lang M; Meyer T; Schoepfer J Bioorg Med Chem Lett; 2008 Feb; 18(3):897-900. PubMed ID: 18248988 [TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of new potent and highly selective ROS1-tyrosine kinase inhibitor. Park BS; El-Deeb IM; Yoo KH; Oh CH; Cho SJ; Han DK; Lee HS; Lee JY; Lee SH Bioorg Med Chem Lett; 2009 Aug; 19(16):4720-3. PubMed ID: 19596575 [TBL] [Abstract][Full Text] [Related]
18. Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors. Das J; Moquin RV; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K Bioorg Med Chem Lett; 2008 Apr; 18(8):2652-7. PubMed ID: 18359226 [TBL] [Abstract][Full Text] [Related]
19. Identification of 4-aminopyrazolylpyrimidines as potent inhibitors of Trk kinases. Wang T; Lamb ML; Scott DA; Wang H; Block MH; Lyne PD; Lee JW; Davies AM; Zhang HJ; Zhu Y; Gu F; Han Y; Wang B; Mohr PJ; Kaus RJ; Josey JA; Hoffmann E; Thress K; Macintyre T; Wang H; Omer CA; Yu D J Med Chem; 2008 Aug; 51(15):4672-84. PubMed ID: 18646745 [TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of benzoazepin-2-one analogs as allosteric binders targeting the PIF pocket of PDK1. Wei L; Gao X; Warne R; Hao X; Bussiere D; Gu XJ; Uno T; Liu Y Bioorg Med Chem Lett; 2010 Jul; 20(13):3897-902. PubMed ID: 20627557 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]